Javascript must be enabled to continue!

Data from Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma

<div>AbstractPurpose: Despite the recent advances made in the treatment of multiple myeloma, the disease still remains incurable. The oncolytic potential of reovirus has previously been shown and is currently in phase III clinical trials for solid tumors. We tested the hypothesis that reovirus can successfully target human multiple myeloma in vitro, ex vivo, and in vivo without affecting human hematopoietic stem cell (HHSC) re-population/differentiation in a murine model that partially recapitulates human multiple myeloma.Experimental Design: Human myeloma cell lines and ex vivo tumor specimens were exposed to reovirus and oncolysis and mechanisms of cell death were assessed. RPMI 8226GFP+ cells were injected intravenously to non-obese diabetic/severe combined immune deficient (NOD/SCID) mice and treated with live reovirus (LV) or dead virus (DV). Multiple myeloma disease progression was evaluated via whole-body fluorescence and bone marrow infiltration. HHSCs exposed to LV/DV were injected to NOD/SCID mice and re-population/differentiation was monitored.Results: A total of six of seven myeloma cell lines and five of seven patient tumor specimens exposed to reovirus showed significant in vitro sensitivity. Tumor response of multiple myeloma by LV, but not DV, was confirmed by comparison of total tumor weights (P = 0.05), and bone marrow infiltration (1/6, LV; 5/6, DV). Mice injected with LV- or DV-exposed HHSCs maintained in vivo re-population/lineage differentiation showing a lack of viral effect on the stem cell compartment. Reovirus oncolysis was mediated primarily by activation of the apoptotic pathways.Conclusions: The unique ability of reovirus to selectively kill multiple myeloma while sparing HHSCs places it as a promising systemic multiple myeloma therapeutic for clinical testing. Clin Cancer Res; 18(18); 4962–72. ©2012 AACR.</div>

American Association for Cancer Research (AACR)

Chandini M. Thirukkumaran Zhong Qiao Shi Joanne Luider Karen Kopciuk He Gao Nizar Bahlis Paola Neri Mark Pho Douglas Stewart Adnan Mansoor Don G. Morris

2023

Title: Data from Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma

Description:

<div>AbstractPurpose: Despite the recent advances made in the treatment of multiple myeloma, the disease still remains incurable.

The oncolytic potential of reovirus has previously been shown and is currently in phase III clinical trials for solid tumors.

We tested the hypothesis that reovirus can successfully target human multiple myeloma in vitro, ex vivo, and in vivo without affecting human hematopoietic stem cell (HHSC) re-population/differentiation in a murine model that partially recapitulates human multiple myeloma.

Experimental Design: Human myeloma cell lines and ex vivo tumor specimens were exposed to reovirus and oncolysis and mechanisms of cell death were assessed.

RPMI 8226GFP+ cells were injected intravenously to non-obese diabetic/severe combined immune deficient (NOD/SCID) mice and treated with live reovirus (LV) or dead virus (DV).

Multiple myeloma disease progression was evaluated via whole-body fluorescence and bone marrow infiltration.

HHSCs exposed to LV/DV were injected to NOD/SCID mice and re-population/differentiation was monitored.

Results: A total of six of seven myeloma cell lines and five of seven patient tumor specimens exposed to reovirus showed significant in vitro sensitivity.

Tumor response of multiple myeloma by LV, but not DV, was confirmed by comparison of total tumor weights (P = 0.

05), and bone marrow infiltration (1/6, LV; 5/6, DV).

Mice injected with LV- or DV-exposed HHSCs maintained in vivo re-population/lineage differentiation showing a lack of viral effect on the stem cell compartment.

Reovirus oncolysis was mediated primarily by activation of the apoptotic pathways.

Conclusions: The unique ability of reovirus to selectively kill multiple myeloma while sparing HHSCs places it as a promising systemic multiple myeloma therapeutic for clinical testing.

Clin Cancer Res; 18(18); 4962–72.

</div>.

Back

Abstract Introduction: Multiple myeloma (MM) is an incurable hematologic malignancy that accounts for 10% of hematopoietic neoplasms. Recently we have demonstrated t...

Data from Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma

<div>AbstractPurpose: Despite the recent advances made in the treatment of multiple myeloma, the disease still remains incurable. The oncolytic po...

Abstract 591: Reovirus is oncolytic towards organ specific and highly metastatic lung cancer cells: Possible mechanisms of action.

Abstract Introduction: Metastasis from lung adenocarcinoma can occur rapidly to multiple organs within months of diagnosis. Despite early diagnosis and surgical remo...

Oncolytic Reovirus Infection Is Facilitated by the Autophagic Machinery

Mammalian reovirus is a double-stranded RNA virus that selectively infects and lyses transformed cells, making it an attractive oncolytic agent. Despite clinical evidence for anti-...

Plasma Cell Disorders

Multiple myeloma represents 1.4% of all new patients with cancer and will result in an estimated 11,090 deaths in 2014. It is twice as common in black men as in white men and 2.5 t...

Plasma Cell Disorders

Multiple myeloma represents 1.4% of all new patients with cancer and will result in an estimated 11,090 deaths in 2014. It is twice as common in black men as in white men and 2.5 t...

MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma

Abstract Multiple myeloma (MM) is a malignancy of terminally differentiated clonal plasma cells displaying significant molecular heterogeneity with 7 subgroups defin...

Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage

<div>AbstractPurpose: B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this stud...

Email:
Password:

Email:

Data from Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma

Related Results